Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019’s EUCAST Proposed Breakpoint Changes

Matthaios Papadimitriou-Olivgeris 1,*,†, Christina Bartzavali 2, Alexandra Nikolopoulou 3, Fevronia Kolonitsiou 2, Virginia Mplani 3, Iris Spiliopoulou 2, Myrto Christofidou 2, Fotini Fligou 3 and Markos Marangos 1

1 Division of Infectious Diseases, School of Medicine, University of Patras, 265 04 Patras, Greece; marangos@upatras.gr
2 Department of Microbiology, School of Medicine, University of Patras, 265 04 Patras, Greece; chrisbartzavali@gmail.com (C.B.); kolonits@upatras.gr (F.K.); spiliopl@upatras.gr (I.S.); christof@upatras.gr (M.C.)
3 Anesthesiology and Critical Care Medicine, School of Medicine, University of Patras, 265 04 Patras, Greece; alex.nikolo.1981@gmail.com (A.N.); Virginiamplani@yahoo.gr (V.M.); ffilig@yahoo.com (F.F.)

* Correspondence: Matthaios.Papadimitriou-Olivgeris@chuv.ch; Tel.: +41-795-565-695
† Present address: Infectious Diseases Service, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Received: 27 October 2020; Accepted: 18 November 2020; Published: 19 November 2020

Abstract: Background: Tigecycline is a therapeutic option for carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Our aim was to evaluate the impact of the tigecycline’s minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp bacteraemia treated with tigecycline monotherapy. Methods: Patients with monomicrobial bacteraemia due to CP-Kp that received appropriate targeted monotherapy or no appropriate treatment were included. Primary outcome was 30-day mortality. MICs of meropenem, tigecycline, and ceftazidime/avibactam were determined by Etest, whereas for colistin, the broth microdilution method was applied. PCR for blaKPC, blaVIM, blaNDM, and blaOXA genes was applied. Results: Among 302 CP-Kp bacteraemias, 32 isolates (10.6%) showed MICs of tigecycline ≤ 0.5 mg/L, whereas 177 (58.6%) showed MICs that were 0.75–2 mg/L. Colistin and aminoglycoside susceptibility was observed in 43.0% and 23.8% of isolates, respectively. The majority of isolates carried blaKPC (249; 82.5%), followed by blaVIM (26; 8.6%), both blaKPC and blaVIM (16; 5.3%), and blaNDM (11; 3.6%). Fifteen patients with tigecycline MIC ≤ 0.5 mg/L and 55 with MIC 0.75–2 mg/L were treated with tigecycline monotherapy; 30-day mortality was 20.0% and 50.9%, respectively (p = 0.042). Mortality of 150 patients that received other antimicrobials was 24.7%; among 82 patients that received no appropriate treatment, mortality was 39.0%. No difference in 30-day mortality was observed between patients that received tigecycline (MIC ≤ 0.5 mg/L) or other antimicrobials. Conclusion: Tigecycline monotherapy was as efficacious as other antimicrobials in the treatment of bloodstream infections due to CP-Kp isolates with a tigecycline’s MIC ≤ 0.5 mg/L.

Keywords: tigecycline; bloodstream infection; carbapenemase; carbapenem-resistance; ceftazidime/avibactam; colistin; mortality
1. Introduction

Carbapenemase-producing *Klebsiella pneumoniae* (CP-Kp) has become a significant global public health challenge [1]. The arrival of novel beta-lactam/beta-lactamase inhibitor combinations, such as ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, the siderophore cephalosporin, cefiderocol, and a next-generation aminoglycoside, plazomicin, has increased the available treating options in our arsenal, improving the outcome of such infections [2]. Previously, the available antimicrobial treatment options were colistin, tigecycline, aminoglycosides, fosfomycin, and carbapenems [3,4]. Combination therapy has been proposed as the best choice, but there are no clear data showing which combination therapy is superior [5].

Tigecycline is the first member of the glycylcycline class, has a broad spectrum of antibacterial activity, and achieves adequate levels into different tissues [6]. It has been approved for community-acquired pneumonia, skin and soft-tissue, and intraabdominal infections [6]. The use of tigecycline in bacteremia is controversial because of its low serum levels with standard dosing [7]. Despite such limitation, tigecycline is a useful alternative for the treatment of infections due to CP-Kp and has been shown to be an effective and safe drug for the treatment of severe CP-Kp infections [8,9]. In observational studies, tigecycline was equally effective to other options (colistin, aminoglycosides, carbapenems) even when used as monotherapy [8,9].

In 2019, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) revised the minimum inhibitory concentration (MIC) breakpoints for tigecycline [10]; prior to 2019, an isolate was considered susceptible if the MIC was \(< 1\) mg/L and resistant if MIC was \(> 2\) mg/L [11]; since 2019, an isolate with MIC \(> 0.5\) mg/L has been considered resistant [10]. This revision rendered most of the isolates that were previously considered as susceptible to be considered resistant [12].

The aim of the present study was to evaluate the impact of the tigecycline’s MIC in the outcome of critically ill patients with CP-Kp bacteraemia treated with tigecycline monotherapy.

2. Results

In total, 302 episodes of monomicrobial bloodstream infections (BSIs) due to CP-Kp were included. Most BSIs were primary (131; 43.4%) and catheter-related (111; 36.8%); the remaining bacteraemias were associated with ventilator-associated pneumonia (24; 7.9%), abdominal infection (22; 7.3%), meningitis (7; 2.3%), urinary tract infection (6; 2.0%) and deep surgical site infection (1; 0.3%). The majority carried bla\(_{ \text{KPC} }\) (249; 82.5%), followed by bla\(_{ \text{VIM} }\) (26; 8.6%), both bla\(_{ \text{KPC} }\) and bla\(_{ \text{VIM} }\) (16; 5.3%), and bla\(_{ \text{NDM} }\) (11; 3.6%) (Supplementary Materials). Two isolates (0.7%) had MIC \(< 8\) mg/L to tested carbapenem (imipenem, meropenem). Concerning tigecycline, 32 isolates (10.6%) showed MIC \(< 0.5\) mg/L and 177 (58.6%) MICs ranging from 0.75 to 2 mg/L (Table 1). Susceptibility rates for aztreonam, sulfamethoxazole-trimethoprim, and ciprofloxacin were 2.3%, 4.3%, and 0.7%, respectively. Colistin and aminoglycoside susceptibility was observed in 43.0% and 23.8% of isolates, respectively. Fosfomycin and ceftazidime/avibactam were tested in 58 and 24 isolates, respectively; among them, 29 (50.0%) and 21 (87.5%) were susceptible.

Table 1. Minimum inhibitory concentration (MIC) distribution and susceptibility of 302 carbapenemase-producing *Klebsiella pneumoniae* isolates to different antimicrobials according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.

| MIC (mg/L) | EUCAST |
|-----------|---------|
|           | S (%)   | R (%)   |
| 0.125     | 32 (10.6)| 270 (89.4)|
| 0.25      | 20      | 152     |
| 0.38      | 22      | 156     |
| 0.5       | 52      | 146     |
| 0.75      | 53      | 144     |
| 1         | 18      | 281     |
| 1.5       | 12      | 283     |
| 2         | 3       | 287     |
| 3         | 7       | 290     |
| 4         | 32      | 295     |
| 6         | 12      | 303     |
| 8         | 3       | 306     |
| 12        | 7       | 311     |

Resistant isolates according to EUCAST appear in bold. S: susceptible; R: resistant.
Group A (tigecycline monotherapy; MIC of tigecycline ≤ 0.5 mg/L) and B (tigecycline monotherapy; MIC of tigecycline 0.75–2 mg/L) included 15 and 55 patients, respectively; the 30-day mortality was 20.0% and 50.9%, respectively. Group C (appropriate targeted monotherapy other than tigecycline) included 150 patients and had a 30-day mortality of 24.7%; the repartition of antimicrobials received was 111 colistin, 29 aminoglycoside, 8 ceftazidime/avibactam, and 2 carbapenems (MIC of imipenem and meropenem ≤ 4 mg/L). Group D (no appropriate targeted therapy) included 82 patients and had a 30-day mortality of 39.0%. The univariate analyses comparing different groups are shown in Table 2. Compared with Group A, Group B showed a statistically higher mortality (p = 0.042), while no difference in types of infections or septic shock occurrence or comorbidities was observed. No difference in 30-day mortality was observed among patients in Groups A and C. In addition, patients receiving appropriate monotherapy (Group A and C) had significantly lower 30-day mortality (p < 0.001) as compared to those that did not (Group B and D).

Univariate and multivariate analyses among Group A and Group B patients of predictors of 30-day mortality are shown in Table 3. Multivariate analysis revealed septic shock (p = 0.001; Odds Ratio 7.834, 95% Confidence Interval 2.343–26.198) as the sole independent predictors of mortality.
Table 2. Univariate analyses of characteristics of patients depending on received antibiotic treatment among patients with carbapenemase-producing *K. pneumoniae* (CP-Kp) bloodstream infection (BSI) during intensive care unit (ICU) hospitalization.

| Characteristics                  | Group A (N = 15) | Group B (N = 55) | Group C (N = 150) | Group D (N = 82) |
|----------------------------------|------------------|------------------|-------------------|------------------|
|                                  | Tigecycline Monotherapy (MIC ≤ 0.5 Mg/L) | Tigecycline Monotherapy (MIC 0.75–2 Mg/L) | Monotherapy Other Than Tigecycline | No Appropriate Treatment |
| Age (years)                      | 47.3 ± 18.2      | 58.4 ± 17.9      | 55.1 ± 17.5       | 55.7 ± 17.1      |
| Male gender                      | 10 (66.7%)       | 38 (69.1%)       | 110 (73.3%)       | 57 (69.5%)       |
| Charlson Comorbidity Index       | 2.3 ± 3.1        | 3.6 ± 3.7        | 3.5 ± 3.5         | 2.9 ± 3.2        |
| Obesity                          | 3 (20.0%)        | 18 (32.7%)       | 40 (26.7%)        | 25 (30.5%)       |
| Infection data                   |                  |                  |                   |                  |
| Days at risk                     | 39.0 ± 69.1      | 26.5 ± 25.9      | 19.6 ± 27.0       | 28.5 ± 36.9      |
| Type of bacteraemia              |                  |                  |                   |                  |
| Primary                          | 6 (40.0%)        | 28 (50.9%)       | 60 (40.0%)        | 37 (45.1%)       |
| Catheter-related                 | 4 (26.7%)        | 15 (27.3%)       | 65 (43.3%)        | 27 (32.9%)       |
| Other                            | 5 (33.3%)        | 12 (21.8%)       | 25 (16.7%)        | 18 (22.0%)       |
| Septic shock                     | 7 (46.7%)        | 34 (61.8%)       | 62 (41.3%)        | 32 (39.0%)       |
| SAPS II upon onset of infection  | 39.5 ± 11.3      | 41.4 ± 13.1      | 39.9 ± 11.4       | 41.3 ± 13.2      |
| SOFA score upon onset of infection| 7.3 ± 4.0       | 8.4 ± 3.6        | 7.2 ± 3.3         | 7.4 ± 3.5        |
| Hemofiltration                   | 1 (6.7%)         | 4 (7.3%)         | 11 (7.3%)         | 8 (9.8%)         |
| Outcome                          |                  |                  |                   |                  |
| 30-day mortality                 | 3 (20.0%)        | 28 (50.9%)       | 37 (24.7%)        | 32 (39.0%)       |

Data are number (%) of patients or mean ± standard deviation. SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment. *a* Comparison between Group A and B. *b* 111 colistin, 29 aminoglycoside, 8 ceftazidime/avibactam, and 2 carbapenems. *c* Comparison between Group A and C. *d* Comparison between Groups A and C against Groups B and D. *e* Comparison of primary BSIs against secondary ones. *f* 24 ventilator-associated pneumonias, 22 abdominal infections, 7 meningitis, 6 urinary tract infections, and 1 deep surgical site infection.
Table 3. Univariate and multivariate analyses of predictors of 30-day mortality among Groups A and B patients with carbapenemase-producing *K. pneumoniae* (CP-Kp) bloodstream infection (BSI) during intensive care unit (ICU) hospitalization.

| Characteristics          | Univariate Analysis | Multivariate Analysis |
|--------------------------|---------------------|-----------------------|
|                         | Survivors (N = 39)  | Non-Survivors (N = 31) | p       | p       | OR (95% CI) |
| Age (years)              | 53.4 ± 17.5         | 61.6 ± 16.3           | 0.001   |        |             |
| Male gender              | 27 (69.2%)          | 21 (67.7%)            | 1.000   |        |             |
| Charlson Comorbidity Index | 2.9 ± 3.4           | 4.5 ± 3.4             | 0.016   | 0.227  | 1.100 (0.942–1.283) |
| Obesity                  | 10 (25.6%)          | 11 (35.5%)            | 0.436   |        |             |
| Infection data           |                     |                      |         |        |             |
| Days at risk             | 25.0 ± 35.4         | 22.1 ± 25.5           | 0.636   |        |             |
| Type of bacteraemia      |                     |                      |         |        |             |
| Primary                  | 20 (51.3%)          | 14 (45.2%)            |         |        |             |
| Catheter-related         | 14 (35.9%)          | 5 (16.1%)             | 0.104   | *       |             |
| Other b                  | 5 (13.7%)           | 12 (38.2%)            |         |        |             |
| Septic shock             | 15 (38.5%)          | 26 (83.9%)            | <0.001  | 0.001  | 7.834 (2.343–26.198) |
| SAPS II upon onset of infection | 37.4 ± 9.9       | 51.4 ± 13.0           | 0.001   |        |             |
| SOFA score upon onset of infection | 6.4 ± 2.8   | 10.7 ± 3.4            | <0.001  |        |             |
| Hemofiltration           | 2 (5.1%)            | 3 (9.7%)              | 1.000   |        |             |
| Tigecycline MIC ≤ 0.5 mg/L | 12 (30.8%)         | 3 (9.7%)              | 0.042   | 0.069  | 0.242 (0.052–1.118) |

Data are number (%) of patients or mean ± standard deviation. OR: odds ratio; CI: confidence interval; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment. * Comparison between catheter-related bacteraemia and all other types of infection. b Seven ventilator-associated pneumonias, five abdominal infections, three meningitis, one urinary tract infection, and one deep surgical site infection.

3. Discussion

In the last decades, there has been an important paucity of agents for adequately treating patients with CP-Kp bacteraemia [4]. Before the revision of tigecycline’s breakpoints, resistance rates to tigecycline were lower than other treatment options, such as colistin or aminoglycosides, leading to its wide use [3,12,13]. In 2019, the revision of tigecycline’s breakpoints resulted in a significant change of its susceptibility rates; in the present study, 89.4% of isolates were resistant according to 2019’s EUCAST breakpoints, whereas if the previous breakpoints were used, the resistance rate would drop to 30.8%. The latter rate represented the resistance rate reported in other studies conducted before the change of breakpoints [13,14].

The benefit of combination treatment over monotherapy remains a matter of debate when treating such infections, with some studies favoring the use of combination treatment, especially in critically ill patients [9,13,14]. Concerning monotherapy, tigecycline was considered as efficacious as other options for the treatment of CP-Kp infections [8,9,15]. Moreover, in a meta-analysis, in the subgroup of 398 KPC-producing *K. pneumoniae* bacteraemias, tigecycline was better than the other options [9].

Our data validate the change proposed by EUCAST in 2019, since the outcome of bacteraemias treated with tigecycline with MICs between 0.75 and 2 mg/L was worse than that of with MICs ≤ 0.5 mg/L, and comparable to those receiving no appropriate targeted treatment [10]. If the isolate’s MIC was ≤ 0.5 mg/L, tigecycline monotherapy was as efficacious as monotherapy with other treatment options (colistin, aminoglycoside, ceftazidime/avibactam, or carbapenems).

A main concern regarding the use of tigecycline to treat CP-Kp bacteraemias is the suboptimal concentrations, which could be overcome by increasing the dose, leading to better outcomes [7]. While this can be true for some types of infections, such as intra-abdominal or lower respiratory tract infections, bacteraemias represent difficult-to-treat infections, especially in critically ill patients. In an in vitro model, the standard tigecycline dose (100 mg/day) could be sufficient to treat bacteraemias by isolates with MICs < 0.06 mg/L, while a double dose (200 mg/day) was necessary for isolates with MICs of 0.125 to 0.25 mg/L [16]. Thus, the doses administered would not be sufficient to treat the majority of patients with CP-Kp bacteraemia [3,13,14].

This study has several limitations. It is a retrospective study in a Greek ICU with a moderate number of patients. The number of patients that received tigecycline for bacteraemia due to a CP-Kp isolate with tigecycline’s MIC ≤ 0.5 mg/L was small. While tigecycline was compared to other antimicrobials
combined, no analysis was performed separately, since most of the patients in Group C received colistin and the other options (aminoglycoside, ceftazidime/avibactam, carbapenems) were underrepresented.

4. Materials and Methods

This retrospective study was carried out in the intensive care unit (ICU) of the University General Hospital of Patras (UGHP), Greece, during a ten-year period (2010–2019). The Ethical Committee of the UGHP approved the study (No 858).

Patients with a monomicrobial bacteraemia due to CP-Kp that received appropriate targeted monotherapy or no appropriate targeted treatment were included in the study. Those who received two or more appropriate antimicrobials were excluded. Groups A and B comprised of patients treated with tigecycline monotherapy, of which the infecting isolate had MICs of tigecycline \( \leq 0.5 \text{ mg/L} \) and \( 0.75-2 \text{ mg/L} \), respectively. Group C included patients treated with appropriate targeted monotherapy of colistin, aminoglycoside, ceftazidime/avibactam, or carbapenem, while Group D included patients that did not receive appropriate targeted therapy. Multiple episodes of bacteraemia from the same patient were included if a duration of at least two months occurred between two episodes.

Primary outcome was 30-day mortality. Data (epidemiological, comorbidities, antimicrobial administration, types of infection, and outcome) were obtained from patients’ chart reviews and the ICU computerized database (Criticus™, University of Patras, Patras, Greece). Primary or secondary BSI was determined in accordance to the Centers for Disease Control and Prevention definition [17]. Infection was categorized as sepsis or septic shock according to new sepsis definition [18]. The date of collection of the first positive blood culture was defined as infection onset.

*K. pneumoniae* isolates from clinical specimens of patients hospitalized in UGHP were identified by the Vitek 2 Advanced Expert System (bioMérieux, Marcy-l’Étoile, France). Antimicrobial susceptibility testing was performed by the agar disk diffusion method against imipenem, meropenem, aztreonam, amikacin, gentamicin, sulfamethoxazole-trimethoprim, and ciprofloxacin. Minimum inhibitory concentrations (MICs) of imipenem, meropenem, tigecycline, fosfomycin, and ceftazidime/avibactam were determined by Etest (bioMérieux, Marcy-l’Étoile, France), whereas the MIC of colistin was determined by the broth microdilution method according to EUCAST methodology. EUCAST criteria were applied to interpret susceptibility result [10]. *bla\_VIM*, *bla\_IMP*, *bla\_KPC*, *bla\_NDM*, and *bla\_OXA* were detected by PCR [19,20].

Data analysis was performed with SPSS version 23.0 (SPSS, Chicago, IL, USA). Fisher exact test or the \( \chi^2 \) test was used for categorical variables and Mann–Whitney \( U \)-test for continuous ones. Multiple logistic regression analysis was used to identify independent predictors of 30-day mortality. A \( p \) value < 0.05 was considered significant.

5. Conclusions

Tigecycline was as efficacious as other antimicrobials for the treatment of bacteraemia due to CP-Kp isolate with an MIC for tigecycline \( \leq 0.5 \text{ mg/L} \). When tigecycline’s MIC ranged from 0.75 to 2 mg/L, patients’ clinical outcome was comparable to patients that received no appropriate antimicrobial treatment, thus affirming the proposed changes from EUCAST. Tigecycline can be used as monotherapy only if tigecycline’s MIC is \( \leq 0.5 \text{ mg/L} \).

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2079-6382/9/11/828/s1.

**Author Contributions:** Conceptualization: M.C. and M.M.; methodology: C.B., A.N., F.K., V.M., I.S., and F.F.; formal analysis: M.C. and M.P.-O.; investigation: M.P.-O., F.K., A.N., and V.M.; resources: I.S.; data curation: M.P.-O.; writing—original draft preparation: M.P.-O.; writing—review and editing: all authors; supervision: M.M. and M.C.; project administration: M.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Albiger, B.; Glasner, C.; Struelens, M.J.; Grundmann, H.; Monnet, D.L. European survey of carbapenemase-Producing enterobacteriaceae working. g. carbapenemase-producing enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. *Eurosurveillance* **2015**, *20*, 20. [CrossRef] [PubMed]

2. Bassetti, M.; Vena, A.; Sepulcri, C.; Giacobbe, D.R.; Peghin, M. Treatment of bloodstream infections due to gram-negative bacteria with difficult-to-treat resistance. *Antibiotics* **2020**, *9*, 632. [CrossRef] [PubMed]

3. Papadimitriou-Olivgeris, M.; Fligou, F.; Bartonzali, C.; Spyropoulou, A.; Koutsileou, K.; Vamvakopoulou, S.; Sioulas, N.; Karamouzos, V.; Anastassiou, E.D.; et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infection in critically ill patients: Risk factors and predictors of mortality. *Eur. J. Clin. Microbiol. Infect. Dis.* **2017**, *36*, 1125–1131. [CrossRef] [PubMed]

4. Karaiskos, I.; Lagou, S.; Pontikis, K.; Rapti, V.; Poulakou, G. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. *Front. Public Health* **2019**, *7*, 151. [CrossRef] [PubMed]

5. Gutierrez-Gutierrez, B.; Salamanca, E.; de Cueto, M.; Hsueh, P.R.; Viale, P.; Pano-Pardo, J.R.; Venditti, M.; Tumbarello, M.; Daikos, G.; Canton, R.; et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. *Lancet Infect. Dis.* **2017**, *17*, 726–734. [CrossRef] [PubMed]

6. Stein, G.E.; Babinchak, T. Tigecycline: An update. *Diagn. Microbiol. Infect. Dis.* **2013**, *75*, 331–336. [CrossRef] [PubMed]

7. Falagas, M.E.; Vardakas, K.Z.; Tsiveriotis, K.P.; Triaides, N.A.; Tansarli, G.S. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. *Int. J. Antimicrob. Agents* **2014**, *44*, 1–7. [CrossRef] [PubMed]

8. Ni, W.; Han, Y.; Liu, J.; Wei, C.; Zhao, J.; Cui, J.; Wang, R.; Liu, Y. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: A systematic review and meta-analysis. *Medicine* **2016**, *95*, e3126. [CrossRef] [PubMed]

9. Wang, J.; Pan, Y.; Shen, J.; Xu, Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: A systematic review and meta-analysis. *Ann. Clin. Microbiol. Antimicrob.* **2017**, *16*, 24. [CrossRef] [PubMed]

10. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 9.0. 2019. Available online: http://www.eucast.org (accessed on 19 November 2020).

11. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 8.1. 2018. Available online: http://www.eucast.org (accessed on 19 November 2020).

12. Papadimitriou-Olivgeris, M.; Bartonzali, C.; Spyropoulou, A.; Lambropoulou, A.; Sioulas, N.; Vamvakopoulou, S.; Karpetas, G.; Spiliopoulou, I.; Vrettos, T.; Anastassiou, E.D.; et al. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing *Klebsiella pneumoniae* bloodstream infection in critically ill patients during a 7-year period. *Diagn. Microbiol. Infect. Dis.* **2018**, *92*, 235–240. [CrossRef] [PubMed]

13. Kontopidou, F.; Giamarello, H.; Katerelos, P.; Maragos, A.; Kioumis, I.; Trikka-Graphakos, E.; Valakis, C.; Maltezou, H.C.; on behalf of the Group for the Study of KPC-producing *Klebsiella pneumoniae* infections in intensive care units. Infections caused by carbapenem-resistant *Klebsiella pneumoniae* among patients in intensive care units in Greece: A multi-centre study on clinical outcome and therapeutic options. *Clin. Microbiol. Infect.* **2014**, *20*, O117–O123. [CrossRef] [PubMed]

14. Tumbarello, M.; Treacarichi, E.M.; De Rosa, F.; Giannella, M.; Giacobbe, D.R.; Bassetti, M.; Losito, A.R.; Bartoletti, M.; Del Bono, V.; Corcione, S.; et al. Infections caused by KPC-producing *Klebsiella pneumoniae*: Differences in therapy and mortality in a multicentre study. *J. Antimicrob. Chemother.* **2015**, *70*, 2133–2143. [CrossRef] [PubMed]
15. Satlin, M.J.; Kubin, C.J.; Blumenthal, J.S.; Cohen, A.B.; Furuya, E.Y.; Wilson, S.J.; Jenkins, S.G.; Calfee, D.P. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant *Klebsiella pneumoniae* from urine. *Antimicrob. Agents Chemother.* 2011, 55, 5893–5899. [CrossRef] [PubMed]

16. Tsala, M.; Vourli, S.; Daikos, G.L.; Tsakris, A.; Zerva, L.; Mouton, J.W.; Meletiadis, J. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* 2017, 72, 172–180. [CrossRef] [PubMed]

17. Horan, T.C.; Andrus, M.; Dudeck, M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am. J. Infect. Control* 2008, 36, 309–332. [CrossRef] [PubMed]

18. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The third international consensus definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315, 801–810. [CrossRef] [PubMed]

19. Queenan, A.M.; Bush, K. Carbapenemases: The versatile beta-lactamases. *Clin. Microbiol. Rev.* 2007, 20, 440–458. [CrossRef] [PubMed]

20. Nordmann, P.; Poirel, L.; Carrer, A.; Toleman, M.A.; Walsh, T.R. How to detect NDM-1 producers. *J. Clin. Microbiol.* 2011, 49, 718–721. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.